Mithra Signs LSA for Commercialization of Myring™ in Switzerland

  • Mithra grants license to Labatec for commercialization of vaginal contraceptive ring in Switzerland
  • Production of Myring™ at the Mithra CDMO facility in Belgium
  • Agreement follows licensing deals with major international market leaders for commercialization of Myring™
Liege, Belgium, 05 December 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement with Labatec for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland.